Published by Michele Maatouk on 19th December 2022
(Sharecast News) - AstraZeneca said on Monday that its Imfinzi (durvalumab) and Imjudo (tremelimumab) combinations have been recommended for marketing authorisation in the European Union for advanced liver and lung cancers.
URL: http://www.digitallook.com/dl/news/story/33186547/...